Five Medtech Trends Shaping Eurasia's Healthcare Industry in 2026

Subheadline: How regional integration, supply chain reconfiguration, and technological innovation are redefining the medical technology landscape across Eurasia.

Executive Summary

The medical technology (medtech) industry is undergoing a structural transformation, driven by policy shifts, economic pressures, and rapid technological convergence. For Eurasia, a region characterized by diverse healthcare systems, emerging manufacturing hubs, and deepening cross-border trade ties, these trends present both challenges and opportunities. This article examines five critical medtech trends identified by Clarivate's Medtech Trends to Watch 2026 report and assesses their strategic implications for business leaders, investors, and policymakers across the EU, Central Asia, the Caucasus, Türkiye, and the broader Caspian region. By understanding the interplay between global market forces and regional dynamics, stakeholders can position themselves to capitalize on the evolution of healthcare delivery and industrial competitiveness.

Introduction

The global medtech market is at an inflection point. Price pressures, shifting sites of care, supply chain vulnerabilities, and powerful therapeutic disruptors are forcing companies to rethink their operating models. Eurasia, sitting at the crossroads of Europe and Asia, is uniquely exposed to these forces. China's procurement reform, which reverberates across global pricing benchmarks, directly impacts Eurasian manufacturers and exporters. Meanwhile, the region's own push for healthcare modernization and industrial diversification creates fertile ground for new investment and innovation. This analysis distills the five trends that will define the medtech landscape in 2026, offering actionable insights for those navigating this complex environment.

Main Analysis

1. Mainland China's VBP Expansion: Redefining Global Market Economics

Mainland China's national volume-based procurement (VBP) program has evolved from a cost-containment measure into a powerful market-structuring instrument. The latest rounds introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational medtech companies, the implications extend far beyond China's borders. Price benchmarks established by VBP are increasingly referenced in negotiations across emerging markets, including Central Asia and the Caucasus, where healthcare budgets are constrained and procurement agencies seek comparable value.

Why it matters for Eurasia: Eurasian medtech manufacturers, particularly those in Türkiye, the Western Balkans, and Eastern Europe, often compete on cost. The VBP-driven price erosion accelerates the need for differentiation through innovation and cost efficiency. Simultaneously, it creates opportunities for regional producers to fill gaps left by multinationals that may deprioritize China-adjacent markets. Governments in Azerbaijan, Kazakhstan, and Georgia are watching VBP outcomes closely, as they design their own procurement frameworks.

2. Outpatient and ASC Settings: A Growing Focus for Procedure-Based Medtech

The global migration of procedures from hospital inpatient settings to outpatient facilities is a long-term trend that reached new momentum in 2026. The U.S. Centers for Medicare & Medicaid Services (CMS) expanded its Ambulatory Surgical Center (ASC) Covered Procedure List to include higher-acuity procedures, a move that will be observed and potentially emulated in other regions. Across Western Europe, public health systems are incentivizing day surgery to reduce bed pressure and costs. In the private healthcare sectors of Türkiye and the Gulf-adjacent Caucasus, outpatient surgery is expanding rapidly.

Why it matters for Eurasia: Medtech companies operating in Eurasia must adapt their commercial models to serve a more diverse set of care settings. Fewer complex procedures will be performed in hospitals, requiring re-engineered products and service offerings. Manufacturers that can demonstrate cost-effectiveness for outpatient settings—through minimally invasive designs or streamlined logistics—will gain a competitive edge. This shift also stimulates demand for modular equipment and digital workflow tools suitable for lower-resource environments.

3. Trade and Supply Chain Pressures: Reshaping Manufacturing Footprints

Global trade tensions, tariff exposure, and material cost volatility are forcing medtech companies to re-evaluate their manufacturing strategies. The era of concentrated production in low-cost nations is giving way to diversified, multi-regional footprints. For Eurasia, this represents a significant opportunity. Countries such as Türkiye, Poland, and Hungary are emerging as alternative manufacturing bases due to their proximity to EU markets, skilled labor, and improving infrastructure. Meanwhile, Central Asian nations are courting foreign direct investment in medical device production as part of their broader industrialization agendas.

Why it matters for Eurasia: Supply chain resilience is no longer just a corporate buzzword; it is a core strategic imperative. Medtech companies must balance cost with risk, and this is prompting many to pivot toward nearshoring. Eurasian policymakers can capitalize on this trend by offering investment incentives, improving logistics connectivity along the Middle Corridor, and streamlining customs procedures. For existing manufacturers in the region, the turbulence creates opportunities to upgrade capabilities and integration into global supply chains.

4. GLP-1 Therapies: Navigating a Disruption in Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is fundamentally altering how obesity and metabolic diseases are managed. While bariatric surgery remains the most effective intervention for severe weight loss, the demand for GLP-1 drugs is reshaping the competitive landscape for medical devices across multiple therapy areas, including sleep apnea, cardiovascular monitoring, and diabetes care. In Eurasia, prevalence of metabolic syndrome is high, and the availability of these therapies is growing, albeit unevenly. This divergence is creating market fragmentation.

Why it matters for Eurasia: Medtech companies must anticipate the knock-on effects of GLP-1 use. Growth in chronic disease management devices may slow or shift in unexpected ways. The reduction in obesity-related complications could lower demand for certain surgical instruments, while increasing demand for remote monitoring and digital health tools. Regional players should closely monitor adoption rates in western EU markets versus emerging Central Asian markets, where pricing and reimbursement constraints may delay access, maintaining a longer tail for existing surgical solutions.

5. Enabling Technologies and the Rise of Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer peripheral additions to surgical procedures; they are becoming the foundation of competitive advantage. Companies that can integrate these capabilities into end-to-end platforms—covering clinical planning, execution, and postoperative care—are creating deeper customer lock-in. This is not limited to large incumbents. Emerging open-platform systems are lowering entry barriers, allowing new players from the software domain to enter the medtech space.

Why it matters for Eurasia: This shift rewards investments in data and ecosystem integration, areas where Eurasian nations can play a role through their growing tech talent pools. Kazakhstan and Uzbekistan, for example, have ambitions to become digital hubs, while the EU's Digital Single Market provides a regulatory framework for cross-border health data exchange. For medtech companies, succeeding in Eurasia requires partnerships with local tech firms and adaptation to fragmented data systems. The platform approach enables companies to offer value that transcends individual product sales, aligning with long-term strategic development.

Business Impact

These five trends collectively alter the calculus for business competitiveness in Eurasia's medtech sector. Companies must reconcile global price pressures with localized value creation. For instance, the VBP effect necessitates portfolio rationalization, pushing companies to invest in high-value product segments, while divesting commoditized lines. This, in turn, influences capital allocation decisions, supply chain design, and go-to-market strategies within the region.

Manufacturing strategy becomes a locus of competitive differentiation. Those who establish flexible, multi-region production networks can better navigate tariffs and trade disruptions. The shift to outpatient care demands new go-to-market models, including direct collaboration with surgical centers, which are proliferating in Türkiye, Georgia, and the Baltic states. The GLP-1 disruption necessitates predictive analytics to adjust product portfolios and sales forecasts, while the platform trend compels companies to invest heavily in software and AI capabilities, either through acquisition or strategic partnerships.

Regional Perspective

The implications of these trends vary across Eurasia's subregions. In the European Union, stringent regulatory requirements and mature health technology assessment (HTA) processes will filter the adoption of platform technologies. The outpatient shift aligns with efficiency-driven health reforms, while China's VBP may prompt stricter procurement methods in some EU nations. In Central Asia and the Caucasus, where healthcare infrastructure is still evolving, these trends offer a leapfrog opportunity—newer facilities can incorporate outpatient models and digital platforms from the outset, unencumbered by legacy hospital infrastructure.

Türkiye, with its strong manufacturing base and growing tech ecosystem, stands to benefit from supply chain reconfiguration, particularly if it can secure trade agreements that facilitate access to the EU and Middle East. The Western Balkans, aspiring to EU accession, can attract investment in medtech manufacturing by aligning with EU standards. The Caspian region, rich in energy revenues, is funding healthcare modernization, creating demand for high-tech devices but requiring careful pricing strategies given VBP-type pressure in nearby markets.

Future Outlook

Over the next 3–5 years, Eurasia's medtech landscape will be defined by consolidation, regionalization, and digitalization. Expect to see:

• Greater regional supply chain integration as manufacturers diversify across the Middle Corridor, leveraging new rail and port infrastructure to move goods more efficiently.
• Emergence of regional champion medtech companies supported by government industrial policies and investment in R&D.
• Increased cross-border investment in digital health startups and platform technologies, particularly in EU member states and Türkiye.
• Harmonization of procurement practices influenced by China's VBP and comparable reforms in other Eurasian countries, pressuring margins but also creating transparency.
• Expansion of medical tourism driven by outpatient care models, especially in Türkiye and the Caucasus, boosting demand for advanced medtech.

Strategic players will proactively adapt, using scenario planning to anticipate shifts in care pathways and procurement regimes. Policymakers can enhance competitiveness by investing in logistics, education, and digital infrastructure, and by fostering regional cooperation on health technology assessment.

Conclusion

The five medtech trends highlighted by Clarivate—China's VBP expansion, outpatient migration, supply chain reconfiguration, GLP-1 disruption, and platform-based competition—are no longer emerging forces; they are active levers of change. For Eurasia, they coalesce into a clear call to action: embrace diversification, invest in innovation, and build regional linkages. Companies that ignore these dynamics risk erosion of market share and relevance. Those that engage strategically can transform Eurasia's healthcare landscape and establish the region as a competitive global hub for medical technology.

Key Takeaways

• China's VBP is setting global price benchmarks, compelling medtech firms to differentiate through innovation and locally tailored value propositions.
• The shift to outpatient and ASC settings is accelerating across Eurasia, necessitating redesigned products and commercial strategies.
• Supply chain diversification is creating industrial development opportunities in Türkiye, Eastern Europe, and Central Asia.
• GLP-1 therapies are reshaping care pathways, with mixed implications across Eurasia's diverse markets.
• Platform-based competition demands investments in robotics, AI, and digital workflow integration—areas where regional tech talent can contribute significantly.

Sources

• Clarivate, "5 medtech trends to watch in 2026" (April 2026): https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026